Langbahn Team – Weltmeisterschaft

ISTA Pharmaceuticals

ISTA Pharmaceuticals, Inc.
Company typeSubsidiary
Nasdaq: ISTA
IndustryPharmaceuticals
Founded1992; 32 years ago (1992)
HeadquartersIrvine, California
Key people
  • Vicente Anido Jr., Ph.D. (president, CEO)
  • Glenn E. Davis (vice president, Chief Compliance Officer)
  • Marvin J. Garrett (vice president, Regulatory Affairs, Quality & Compliance)
  • Kathleen McGinley (Vice President, Human Resources & Corporate Services)
ProductsBromday, Bepreve, Xibrom, Istalol, Vitrase
Websitewww.istavision.com

ISTA Pharmaceuticals, Inc., was a US-based pharmaceutical company that specialized in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye.[1] ISTA was acquired by Bausch & Lomb, an eye care company, on March 26, 2012.[2] Under the deal, Bausch & Lomb have agreed to pay $9.10 per share for ISTA, bringing the total value of the acquisition to $500 million.[3] In 2012, Valeant Pharmaceuticals withdrew its $360 million offer.[4]

Products

  • Bromday (bromfenac ophthalmic solution) 0.09% for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction[5]
  • Bepreve (bepotastine besilate ophthalmic solution) 1.5% for the treatment of itching associated with signs and symptoms of allergic conjunctivitis[6]
  • Xibrom (bromfenac ophthalmic solution) 0.09% for the treatment of inflammation and pain following cataract surgery (no longer being manufactured as of February 2011)
  • Istalol (timolol maleate ophthalmic solution) 0.5% for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma[7]
  • Vitrase (hyaluronidase injection) Ovine, 200 USP units/mL for use as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents[8]

Litigation

On May 24, 2013, ISTA Pharmaceuticals entered a guilty plea to federal felony charge of conspiracy to introduce a misbranded drug into interstate commerce and conspiracy to pay illegal remuneration in violation of the Federal Anti-Kickback Statute. ISTA agreed to pay $33.5 million to resolve criminal and civil liability arising from its marketing, distribution and sale of its drug Xibrom.[9]

References

  1. ^ "ISTA: Profile for ISTA Pharmaceuticals, Inc. - Yahoo! Finance". Finance.yahoo.com. Retrieved October 28, 2009.
  2. ^ Lattman, Peter (26 March 2012). "Bausch & Lomb to Buy ISTA Pharmaceuticals for $500 Million". DealBook. Retrieved January 29, 2019.
  3. ^ Lattman, Peter (2012-03-26). "Bausch & Lomb to Buy ISTA Pharmaceuticals for $500 Million". DealBook. Retrieved 2019-10-21.
  4. ^ Scott, Mark (4 September 2012). "Valeant Sticks to Torrid Pace of Deal-Making". DealBook. Retrieved January 29, 2019.
  5. ^ "BROMDAY™ | Products". Archived from the original on 2011-07-13. Retrieved March 21, 2011.
  6. ^ "Relief from Allergic Conjunctivitis - BEPREVE : Bausch + Lomb". www.Bausch.com. Retrieved January 29, 2019.
  7. ^ "Bausch Consumer > en > ecp > our-products". www.Bausch.com. Retrieved January 29, 2019.
  8. ^ "Bausch Consumer > en > ecp > our-products". www.Bausch.com. Retrieved January 29, 2019.
  9. ^ "ISTA Pharmaceuticals Inc. Pleads Guilty to Federal Felony Charges; Will Pay $33.5 Million to Resolve Criminal Liability and False Claims Act Allegations". www.Justice.gov. May 24, 2013. Retrieved January 29, 2019.
Quelle: https://en.wikipedia.org/wiki/ISTA_Pharmaceuticals